Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma

Bharat Jasani, Sharon Coleman, Eric Butchart, Eve M.L. Evans, Malcolm Adams, Malcolm Mason, Allen Gibbs, Zsuzsanna Tabi

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Diffuse malignant pleural mesothelioma (MPM) is the third most common lung malignancy showing rising incidence with 250,000 deaths expected from it in Western Europe over the next 35 year. The tumour is generally resistant to conventional treatment and there is urgent need for novel preventative and therapeutic measures to combat this growing public threat. Finding of SV40 DNA sequences in a high proportion (40-90%) of several series of MPM cases, and suggestion of its potential co-carcinogen role provide a rationale for the development of novel anti-MPM vaccines incorporating SV40 gene sequences or antigenic determinants. As a prelude to adopting this approach, general T cell function was examined in relatively early cases of MPM presenting for biopsy or debulking surgery. CD8+ T cell responses were studied using antigenic epitopes of common viral antigens covering a broad range of haplotypes. 74.1% (20/27) of MPM patients and 80% (8/10) of the control subjects showed T cell responsiveness to the viral peptides mix, whilst a small proportion showed SV40 specific recall immunity.

Original languageEnglish
Pages (from-to)2399-2402
Number of pages4
Issue number17-18
Publication statusPublished - Mar 18 2005


  • Immunotherapy
  • Malignant pleural mesothelioma
  • T cell recall responses

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma'. Together they form a unique fingerprint.

Cite this